Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2001

View Archived Issues

Intense search for orally active and selective VLA-4 antagonists under way at Merck

Progenics and Cytogen team up with AlphaVax to develop PSMA ArV vaccine

OriGenix commences phase I clinical trial with topical treatment for genital warts

New platinum compound licensed by NeoOncoRx, heading for phase III

KRX-101 granted fast track status by FDA as treatment for diabetic nephropathy

LJP files IND for second clinical candidate

Further submissions announced for Visudyne

Poliovirus-based HIV vaccine in development at Iguazu

GSK3 inhibitor CT-98023 targets glucose intolerance and insulin resistance of type 2 diabetes

Selective iNOS inhibitor protects against IL-1beta-induced rat pancreatic islet damage

Interneuron initiates U.S. phase III clinical trial with trospium for overactive bladder

Danish investigators report clinical results for stevioside in diabetes at EASD

Corixa and GSK complete resubmission of Bexxar BLA to FDA

Oral insulin sensitizer RWJ-241947/MCC-555 tested in animal models of type 2 diabetes

FDA approves Xeloda/Taxotere combination therapy for metastatic breast cancer

Allergan's Botox cleared in Canada for treatment of axillary hyperhidrosis

Plavix sNDA granted FDA priority review

Regulation of brain Abeta levels via peripheral administration of an anti-Abeta antibody

8-Arylquinoline PDE4 inhibitors useful for asthma, etc.

Clinical benefit of IntraDose not fully demonstrated according to ODAC

Nitrosated and nitrosylated COX-2 inhibitors designed at NitroMed

Celgene synthesizes a number of related TNF-alpha inhibitors

Bicyclic compounds acting as potassium channel inhibitors described by ICAgen

New antiherpesvirus agents from Bayer have a thiazolyl amide structure

Asta Medica patents new antitumor agents that act as microtubule destabilizers

Biomira begins exploratory phase Ib trial of B-cell lymphoma vaccine

Provenge advances towards 2002 BLA submission

Aventis and ViroPharma collaborate on development and promotion of Picovir

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...